Generic placeholder image

Current Molecular Medicine

Author(s): Liang Zhao, Haiping Zheng, Feng Chen, Huasong Lu, Qian Yu, Xuexin Yan, Xinyu Chen, Qianyu Zhang and Qing Bu*

DOI: 10.2174/1566524023666230619123752

DownloadDownload PDF Flyer Cite As
High TLX1 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Lung Adenocarcinoma

Page: [801 - 812] Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

Background: To develop optimal personalized therapy for lung adenocarcinoma (LUAD), potential biomarkers associated with the prognosis are urgently needed. It is unclear what role T Cell Leukemia Homeobox 1 (TLX1) plays in LUAD.

Objective: In this study, TLX1's relationship with LUAD was investigated using TCGA database analysis, bioinformatics analysis, and experimental validation.

Methods: We examined the expression of TLX1 in pan cancer and LUAD, the relationship between TLX1 expression and clinical features, immune infiltration, its diagnostic and prognostic value, as well as TLX1 related pathways. The analysis included various statistical methods, including the Kaplan-Meier method, Cox regression analysis, GSEA, and immune infiltration analysis. TLX1 expression in LUAD cell lines was validated using qRT-PCR.

Result: In LUAD patients, high expression of TLX1 was associated with T stage (P<0.001). High TLX1 expression was associated with worse overall survival (OS) (HR: 1.57; 95% CI: 1.18–2.1; P=0.002). And TLX1 HR: 1.619; 95% CI: 1.012-2.590; P=0.044) was independently correlated with OS in LUAD patients. TLX1 expression was associated with the pathways, including Rho GTPase effectors, DNA repair, TCF dependent signaling in response to WNT, signaling by Nuclear Receptors, signaling by Notch, chromatin-modifying enzymes, ESR-mediated signaling, cellular senescence, and transcriptional regulation by Runx1. TLX1 expression was correlated with aDC, Tcm, and TReg cells. The expression of TLX1 was significantly increased in LUAD cells compared to BEAS-2B cells.

Conclusion: An association between high TLX1 expression and poor survival and immune infiltration was found in LUAD patients. There may be a potential role for TLX1 in diagnosis, prognosis, and immunotherapy for LUAD.

[1]
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non–small cell lung cancer. JAMA 2019; 322(8): 764-74.
[http://dx.doi.org/10.1001/jama.2019.11058] [PMID: 31454018]
[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68(1): 7-30.
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[3]
Chen H, Carrot-Zhang J, Zhao Y, et al. Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat Commun 2019; 10(1): 5472.
[http://dx.doi.org/10.1038/s41467-019-13460-3] [PMID: 31784532]
[4]
Brainard J, Farver C. The diagnosis of non-small cell lung cancer in the molecular era. Mod Pathol 2019; 32(S1): 16-26.
[http://dx.doi.org/10.1038/s41379-018-0156-x] [PMID: 30600321]
[5]
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: Current therapies and new targeted treatments. Lancet 2017; 389(10066): 299-311.
[http://dx.doi.org/10.1016/S0140-6736(16)30958-8] [PMID: 27574741]
[6]
Sun Y, Luo J, Chen Y, et al. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma). Int Immunopharmacol 2020; 80: 106198.
[http://dx.doi.org/10.1016/j.intimp.2020.106198] [PMID: 31954274]
[7]
Ueno Y, Fujisaki K, Hosoda S, et al. Transcription factor Tlx1 marks a subset of lymphoid tissue organizer-like mesenchymal progenitor cells in the neonatal spleen. Sci Rep 2019; 9(1): 20408.
[http://dx.doi.org/10.1038/s41598-019-56984-w] [PMID: 31892733]
[8]
Kawabe T, Muslin AJ, Korsmeyer SJ. HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint. Nature 1997; 385(6615): 454-8.
[http://dx.doi.org/10.1038/385454a0] [PMID: 9009195]
[9]
De Keersmaecker K, Real PJ, Gatta GD, et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med 2010; 16(11): 1321-7.
[http://dx.doi.org/10.1038/nm.2246] [PMID: 20972433]
[10]
Krutikov K, Zheng Y, Chesney A, Huang X, Vaags AK, Evdokimova V. Ectopic TLX1 expression accelerates malignancies in mice deficient in DNA-PK. PLoS One 2014; 9(2): e89649.
[11]
Vanden Bempt M, Demeyer S, Broux M, et al. Cooperative enhancer activation by TLX1 and STAT5 drives development of NUP214-ABL1/TLX1-Positive T cell acute lymphoblastic leukemia. Cancer Cell 2018; 34(2): 271-285.e7.
[http://dx.doi.org/10.1016/j.ccell.2018.07.007] [PMID: 30107177]
[12]
Wang X, He H, Rui W, Xie X, Wang D, Zhu Y. Long non-coding RNA BCAR4 binds to miR-644a and targets TLX1 to promote the progression of bladder cancer. OncoTargets Ther 2020; 13: 2483-90.
[http://dx.doi.org/10.2147/OTT.S232965] [PMID: 32273720]
[13]
Bai R, Shaobo W, Luo R, Wang S, Zhang X, Song L. The relationship between TEAD gene family and prognosis, tumor microenvironment and therapeutic target by pan-cancer analysis 2022.
[14]
Zheng Y, Fei H. High expression of E2F4 is an adverse prognostic factor and related to immune infiltration in oral squamous cell carcinoma. BioMed Res Int 2022; 2022: 1-13.
[http://dx.doi.org/10.1155/2022/4731364] [PMID: 36567912]
[15]
Xu H, Wang H, Li G, Jin X, Chen B. The immune-related gene ELF3 is a novel biomarker for the prognosis of ovarian cancer. Int J Gen Med 2021; 14: 5537-48.
[http://dx.doi.org/10.2147/IJGM.S332320] [PMID: 34531679]
[16]
Lu X, Jing L, Liu S, Wang H, Chen B. miR-149-3p is a potential prognosis biomarker and correlated with immune infiltrates in uterine corpus endometrial carcinoma. Int J Endocrinol 2022; 2022: 1-15.
[http://dx.doi.org/10.1155/2022/5006123] [PMID: 35719192]
[17]
Lin Z, Huang W, Yi Y, et al. LncRNA ADAMTS9-AS2 is a prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma. Int J Gen Med 2021; 14: 8541-55.
[http://dx.doi.org/10.2147/IJGM.S340683] [PMID: 34849000]
[18]
Liang W, Lu Y, Pan X, et al. Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma. Pharm Genomics Pers Med 2022; 15: 985-98.
[http://dx.doi.org/10.2147/PGPM.S384901] [PMID: 36482943]
[19]
Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 2018; 173(2): 400-416.e11.
[http://dx.doi.org/10.1016/j.cell.2018.02.052] [PMID: 29625055]
[20]
Chen Y, Li D, Wang D, Peng H. Comprehensive analysis of Distal-Less homeobox family gene expression in colon cancer 2023; 15(6): 1019-35.
[http://dx.doi.org/10.21203/rs.3.rs-1723161/v1]
[21]
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15(12): 550.
[http://dx.doi.org/10.1186/s13059-014-0550-8] [PMID: 25516281]
[22]
Yu G, Wang LG, Han Y, He QY. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012; 16(5): 284-7.
[http://dx.doi.org/10.1089/omi.2011.0118] [PMID: 22455463]
[23]
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 2005; 102(43): 15545-50.
[http://dx.doi.org/10.1073/pnas.0506580102] [PMID: 16199517]
[24]
Hänzelmann S, Castelo R, Guinney J. GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 2013; 14(1): 7.
[http://dx.doi.org/10.1186/1471-2105-14-7] [PMID: 23323831]
[25]
Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39(4): 782-95.
[http://dx.doi.org/10.1016/j.immuni.2013.10.003] [PMID: 24138885]
[26]
Lin Z, Huang W, Xie Z, Yi Y, Li Z. Expression, clinical significance, immune infiltration, and regulation network of miR-3940-5p in lung adenocarcinoma based on bioinformatic analysis and experimental validation. Int J Gen Med 2022; 15: 6451-64.
[http://dx.doi.org/10.2147/IJGM.S375761] [PMID: 35966511]
[27]
Lu X, Li G, Liu S, Wang H, Chen B. MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer. J Ovarian Res 2021; 14(1): 90.
[http://dx.doi.org/10.1186/s13048-021-00841-w] [PMID: 34238324]
[28]
Wang W, Ren S, Wang Z, Zhang C, Huang J. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level. Int Immunopharmacol 2020; 78: 106077.
[http://dx.doi.org/10.1016/j.intimp.2019.106077] [PMID: 31812070]
[29]
Zhang S, Lu Y, Qi L, Wang H, Wang Z, Cai Z. AHNAK2 is associated with poor prognosis and cell migration in lung adenocarcinoma. BioMed Res Int 2020; 2020: 1-14.
[http://dx.doi.org/10.1155/2020/8571932] [PMID: 32904605]
[30]
Wu S, Wu D, Pan Y, Liu H, Shao Z, Wang M. Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis. Pathol Res Pract 2019; 215(2): 292-301.
[http://dx.doi.org/10.1016/j.prp.2018.11.016] [PMID: 30527357]
[31]
Durinck K, Van Loocke W, Van der Meulen J, et al. Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia. Leukemia 2015; 29(12): 2317-27.
[http://dx.doi.org/10.1038/leu.2015.162] [PMID: 26108691]
[32]
Verneau J, Sautés-Fridman C, Sun CM. Dendritic cells in the tumor microenvironment: Prognostic and theranostic impact. Semin Immunol 2020; 48: 101410.
[http://dx.doi.org/10.1016/j.smim.2020.101410] [PMID: 33011065]
[33]
Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol 2019; 49(8): 1140-6.
[http://dx.doi.org/10.1002/eji.201847659] [PMID: 31257581]